Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver

Molecular Therapy

Volumn 5, Issue 3, 2002, Pages 269-274

  Martín, Francisco ^a   Chowdhury, Simon ^a   Neil, Stuart ^a   Phillipps, Neil ^a   Collins, Mary K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; In vivo targeting; Melanoma; Retrovirus vectors; Vector spreading; Xenografts

Indexed keywords

CHONDROITIN SULFATE; MATRIX METALLOPROTEINASE INHIBITOR; MELANOMA ANTIGEN; PEPTIDE; RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER TRANSPLANTATION; CELL FUSION; CONTROLLED STUDY; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; MELANOMA CELL; MOLECULAR WEIGHT; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; NUDE MOUSE; PROTEIN DEGRADATION; SPLEEN; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENVELOPE; VIRUS STRAIN;

ANIMALIA; MURINAE; MURINE LEUKEMIA VIRUS; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0036194453     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0550     Document Type: Article

References (28)

1. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
2. Cellular Receptors and Viral Glycoproteins Involved in Retroviral Entry
3. Targeting retrovirus entry
4. Peptide-displaying phages for targeted gene delivery?
5. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis
6. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan
7. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells
8. Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: Characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1
9. Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen
10. Effects of diagnostic application of monoclonal antibody on survival in melanoma patients
11. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant mouse antiidiotypic monoclonal antibody MK2-23
12. Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens
13. Receptor co-operation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding
14. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin α v β 3
15. ECM and cell surface proteolysis: Regulating cellular ecology
16. Retrovirus targeting by tropism restriction to melanoma cells
17. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes
18. Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo
19. Modifying the host range properties of retroviral vectors
20. In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies
21. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
22. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors
23. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
24. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct
25. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice
26. High-titer packaging cells producing recombinant retroviruses resistant to human serum
27. Purification and properties of an endothelial cell growth factor from human platelets
28. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell